Use of 'Extended Clearance Concept' in new drug discovery and development; application to a drug classification system and to a design of clinical studies

• In: Keynote 4 - Ensuring public healthcare quality through pharmacopeia standards and related programs on Tuesday, 23 May 2017, 14:00-15:00
• At: Stockholm (Sweden) (2017)
• Type: Presentation
• By: SUGIYAMA, Yuichi (RIKEN Innovation center, Sugiyama laboratory, Yokohama, Japan)
• Co-author(s): Yuichi Sugiyama: Sugiyama Laboratory, Riken, Yokohama, Japan
  
• Abstract:

  Even when drugs ultimately undergo metabolism and/or biliary excretion in the liver, their elimination rate is sometimes determined by the hepatic uptake rate mediated by uptake transporters. Elucidation of the rate-determining process is therefore critical for predicting their hepatic clearance, and their systemic and regional exposures. I will

  ..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login